Somatic alterations as the basis for resistance to targeted therapies.

Somatic alterations as the basis for resistance to targeted therapies.

Item
http://www.wikidata.org/entity/Q38151570
Tumour heterogeneity and the evolution of polyclonal drug resistanceCirculating Cell-Free Tumour DNA in the Management of Cancer.Low-frequency KRAS mutations are prevalent in lung adenocarcinomasThe Role of Eukaryotic and Prokaryotic ABC Transporter Family in Failure of Chemotherapy.Intratumoral heterogeneity, its contribution to therapy resistance and methodological caveats to assessment.Circulating tumor DNA for triple-negative breast cancer diagnosis and treatment decisions.High-grade serous ovarian cancer: the clone wars.EGF receptor family: twisting targets for improved cancer therapies.Synthesis and Biological Evaluation of New Quinoxaline Derivatives of ICF01012 as Melanoma-Targeting Probes.Pathology in drug discovery and development.Analysis of mutation, selection, and epistasis: an informed approach to cancer clinical trials.
P2860

Somatic alterations as the basis for resistance to targeted therapies.

Item
http://www.wikidata.org/entity/Q38151570
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Somatic alterations as the basis for resistance to targeted therapies.
@en
type
label
Somatic alterations as the basis for resistance to targeted therapies.
@en
prefLabel
Somatic alterations as the basis for resistance to targeted therapies.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P356
P1433
P1476
Somatic alterations as the basis for resistance to targeted therapies.
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P5875
P698